Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3
Autore:
Kobayashi, T; Homma, Y;
Indirizzi:
Tokai Univ, Sch Med, Dept Internal Med, Isehara, Kanagawa 2591193, Japan Tokai Univ Isehara Kanagawa Japan 2591193 sehara, Kanagawa 2591193, Japan
Titolo Testata:
JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 10, volume: 41, anno: 2001,
pagine: 1055 - 1058
SICI:
0091-2700(200110)41:10<1055:EOLPOP>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; APOPROTEIN-E PHENOTYPE; HMG-COA REDUCTASE; CHOLESTEROL ABSORPTION; SIMVASTATIN; METABOLISM; INHIBITOR; THERAPY; MEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Homma, Y Tokai Univ, Sch Med, Dept Internal Med, Isehara, Kanagawa 2591193, Japan Tokai Univ Isehara Kanagawa Japan 2591193 anagawa 2591193, Japan
Citazione:
T. Kobayashi e Y. Homma, "Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3", J CLIN PHAR, 41(10), 2001, pp. 1055-1058

Abstract

Effects of 12 weeks of treatment with pravastatin at a dose of 20 mg/day were compared in subjects with type II hyperlipoproteinemia with apo+(lipoprotein) E phenotype E3/2, E3/3, and E4/3. There were no differences in age, body mass index, smoking status, complications, or plasma levels of lipids and apoproteins, except the higher levels of apo E in E3/2 subjects (n = 11) than in E3/3 subjects (n = 84) and E4/3 subjects (n = 28). Plasma levels of low-density lipoprotein cholesterol (LDL-C) were reduced by 47% +/- 8% (mean +/- SD) in E3/2 subjects, 38% +/- 10% in E3/3 subjects, and 26% +/- 12% in E4/3 subjects after 12 weeks of treatment with pravastatin (all p < 0.0001). Plasma levels of apo B were decreased by 40% +/- 12% in E3/2 subjects, 27% 10% in E3/3 subjects, and 18% +/- 14% in E4/3 subjects after 12 weeks of treatment with provastatin (all p < 0.0001). The reduction in plasma levels of LDL-C and apo B was most marked in E3/2 subjects, next in E3/3 subjects, and smallest in E4/3 subjects. The authors conclude that treatment with pravastatin at a dose of 20 mg/day in Japanese subjects is equally effective as 40 mg/day in Western subjects, and apo E polymorphism is a factor to determine the efficacy of pravastatin in Japanese subjects. <(c)> 2001 the American College of Clinical Pharmacology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 00:29:52